{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T22:54:57Z","timestamp":1782168897328,"version":"3.54.5"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":53,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"DOI":"10.1186\/s12957-026-04342-2","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T01:38:57Z","timestamp":1777599537000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Nomogram predicting outcomes in HCC patients treated with TACE-HAIC, TKIs, and PD-1 inhibitors"],"prefix":"10.1186","volume":"24","author":[{"given":"Jie","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangdingxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junbiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxiang","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoqian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,1]]},"reference":[{"issue":"3","key":"4342_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin May-Jun. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin May-Jun"},{"issue":"9","key":"4342_CR2","doi-asserted-by":"publisher","first-page":"706","DOI":"10.2174\/0109298665330781240830042601","volume":"31","author":"W Ye","year":"2024","unstructured":"Ye W, Wang J, Zheng J, Jiang M, Zhou Y, Wu Z. Association between higher expression of Vav1 in hepatocellular carcinoma and unfavourable clinicopathological features and prognosis. Protein Pept Lett. 2024;31(9):706\u201313.","journal-title":"Protein Pept Lett"},{"issue":"1","key":"4342_CR3","doi-asserted-by":"publisher","first-page":"48","DOI":"10.2174\/0113892029308243240709073945","volume":"26","author":"IP Gudivada","year":"2025","unstructured":"Gudivada IP, Amajala KC. Integrative bioinformatics analysis for targeting hub genes in hepatocellular carcinoma treatment. Curr Genomics. 2025;26(1):48\u201380.","journal-title":"Curr Genomics"},{"issue":"Suppl 4","key":"4342_CR4","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1634\/theoncologist.2010-S4-42","volume":"15","author":"R Lencioni","year":"2010","unstructured":"Lencioni R, Chen XP, Dagher L, Venook AP. Treatment of intermediate\/advanced hepatocellular carcinoma in the clinic: how can outcomes be improved? Oncologist. 2010;15(Suppl 4):42\u201352.","journal-title":"Oncologist"},{"issue":"10","key":"4342_CR5","first-page":"e0548","volume":"1","author":"L Wang","year":"2024","unstructured":"Wang L, Cao J, Liu Z, Wu S, Liu Y, Liang R, et al. Enhanced interactions within microenvironment accelerates dismal prognosis in HBV-related HCC after TACE. Hepatol Commun Oct. 2024;1(10):e0548.","journal-title":"Hepatol Commun Oct"},{"key":"4342_CR6","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.2147\/JHC.S339379","volume":"8","author":"J Huang","year":"2021","unstructured":"Huang J, Huang W, Zhan M, Guo Y, Liang L, Cai M, et al. Drug-eluting bead transarterial chemoembolization combined with FOLFOX-based hepatic arterial infusion chemotherapy for large or huge hepatocellular carcinoma. J Hepatocell Carcinoma. 2021;8:1445\u201358.","journal-title":"J Hepatocell Carcinoma"},{"key":"4342_CR7","doi-asserted-by":"publisher","first-page":"980214","DOI":"10.3389\/fonc.2022.980214","volume":"12","author":"L Sun","year":"2022","unstructured":"Sun L, Xu X, Meng F, Liu Q, Wang H, Li X, et al. Lenvatinib plus transarterial chemoembolization with or without immune checkpoint inhibitors for unresectable hepatocellular carcinoma: A review. Front Oncol. 2022;12:980214.","journal-title":"Front Oncol"},{"key":"4342_CR8","doi-asserted-by":"publisher","first-page":"609322","DOI":"10.3389\/fmolb.2020.609322","volume":"7","author":"L Zheng","year":"2020","unstructured":"Zheng L, Fang S, Wu F, Chen W, Chen M, Weng Q, et al. Efficacy and safety of TACE combined with sorafenib plus immune checkpoint inhibitors for the treatment of intermediate and advanced TACE-refractory hepatocellular carcinoma: a retrospective study. Front Mol Biosci. 2020;7:609322.","journal-title":"Front Mol Biosci"},{"key":"4342_CR9","doi-asserted-by":"publisher","first-page":"1466113","DOI":"10.3389\/fimmu.2024.1466113","volume":"15","author":"Y Chen","year":"2024","unstructured":"Chen Y, Jia L, Li Y, Cui W, Wang J, Zhang C, et al. Efficacy and safety of transarterial chemoembolization plus lenvatinib combined with PD-1 inhibitors versus transarterial chemoembolization plus lenvatinib for unresectable hepatocellular carcinoma: a meta-analysis. Front Immunol. 2024;15:1466113.","journal-title":"Front Immunol"},{"issue":"1","key":"4342_CR10","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1186\/s40425-019-0824-5","volume":"29","author":"M Hilmi","year":"2019","unstructured":"Hilmi M, Neuzillet C, Calderaro J, Lafdil F, Pawlotsky JM, Rousseau B. Angiogenesis and immune checkpoint inhibitors as therapies for hepatocellular carcinoma: current knowledge and future research directions. J Immunother Cancer Nov. 2019;29(1):333.","journal-title":"J Immunother Cancer Nov"},{"issue":"4","key":"4342_CR11","doi-asserted-by":"publisher","first-page":"532","DOI":"10.2174\/0115665232308821240826075513","volume":"25","author":"L Qi","year":"2025","unstructured":"Qi L, Tan Y, Zhou Y, Dong Y, Yang X, Chang S, et al. Proteogenomic Identification and Analysis of KIF5B as a prognostic signature for hepatocellular carcinoma. Curr Gene Ther. 2025;25(4):532\u201345.","journal-title":"Curr Gene Ther"},{"issue":"5","key":"4342_CR12","doi-asserted-by":"publisher","first-page":"453","DOI":"10.2174\/1566523222666220825110147","volume":"24","author":"C Liu","year":"2024","unstructured":"Liu C, Shi J, Lin B, Zhou M, Shan D, Nie J, et al. SHR6390 Combined with cabozantinib inhibits tumor progression in the hepatocellular carcinoma mouse model. Curr Gene Ther. 2024;24(5):453\u201364.","journal-title":"Curr Gene Ther"},{"issue":"4","key":"4342_CR13","doi-asserted-by":"publisher","first-page":"e173","DOI":"10.1016\/S1470-2045(14)71116-7","volume":"16","author":"VP Balachandran","year":"2015","unstructured":"Balachandran VP, Gonen M, Smith JJ, DeMatteo RP. Nomograms in oncology: more than meets the eye. Lancet Oncol Apr. 2015;16(4):e173\u201380.","journal-title":"Lancet Oncol Apr"},{"key":"4342_CR14","doi-asserted-by":"publisher","first-page":"101705","DOI":"10.1016\/j.tranon.2023.101705","volume":"34","author":"B Liu","year":"2023","unstructured":"Liu B, Gao S, Guo J, Kou F, Liu S, Zhang X, et al. A novel nomogram for predicting the overall survival in patients with unresectable HCC after TACE plus hepatic arterial infusion chemotherapy. Transl Oncol Aug. 2023;34:101705.","journal-title":"Transl Oncol Aug"},{"issue":"5","key":"4342_CR15","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1097\/JS9.0000000000000256","volume":"1","author":"Y Yuan","year":"2023","unstructured":"Yuan Y, He W, Yang Z, Qiu J, Huang Z, Shi Y, et al. TACE-HAIC combined with targeted therapy and immunotherapy versus TACE alone for hepatocellular carcinoma with portal vein tumour thrombus: a propensity score matching study. Int J Surg May. 2023;1(5):1222\u201330.","journal-title":"Int J Surg May"},{"key":"4342_CR16","doi-asserted-by":"publisher","first-page":"950266","DOI":"10.3389\/fonc.2022.950266","volume":"12","author":"X Li","year":"2022","unstructured":"Li X, Fu Z, Chen X, Cao K, Zhong J, Liu L, et al. Efficacy and safety of lenvatinib combined with PD-1 inhibitors plus TACE for unresectable hepatocellular carcinoma patients in china real-world. Front Oncol. 2022;12:950266.","journal-title":"Front Oncol"},{"issue":"12","key":"4342_CR17","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/S1470-2045(23)00469-2","volume":"24","author":"JM Llovet","year":"2023","unstructured":"Llovet JM, Kudo M, Merle P, Meyer T, Qin S, Ikeda M, et al. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial. Lancet Oncol Dec. 2023;24(12):1399\u2013410.","journal-title":"Lancet Oncol Dec"},{"issue":"1","key":"4342_CR18","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1186\/s12885-019-6011-8","volume":"27","author":"LX Zhang","year":"2019","unstructured":"Zhang LX, Lv Y, Xu AM, Wang HZ. The prognostic significance of serum gamma-glutamyltransferase levels and AST\/ALT in primary hepatic carcinoma. BMC Cancer Aug. 2019;27(1):841.","journal-title":"BMC Cancer Aug"},{"key":"4342_CR19","doi-asserted-by":"publisher","first-page":"m441","DOI":"10.1136\/bmj.m441","volume":"18","author":"RD Riley","year":"2020","unstructured":"Riley RD, Ensor J, Snell KIE, Harrell FE Jr., Martin GP, Reitsma JB, et al. Calculating the sample size required for developing a clinical prediction model. Bmj Mar. 2020;18:368:m441.","journal-title":"Bmj Mar"},{"issue":"1","key":"4342_CR20","first-page":"58","volume":"8","author":"HD Zhu","year":"2023","unstructured":"Zhu HD, Li HL, Huang MS, Yang WZ, Yin GW, Zhong BY, et al. Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001). Signal Transduct Target Ther. Feb. 2023;8(1):58.","journal-title":"Feb"},{"issue":"1","key":"4342_CR21","doi-asserted-by":"publisher","first-page":"346","DOI":"10.21037\/jgo-23-821","volume":"29","author":"J Yang","year":"2024","unstructured":"Yang J, Shang X, Li J, Wei N. Comparative study on the efficacy and safety of transarterial chemoembolization combined with hepatic arterial infusion chemotherapy for large unresectable hepatocellular carcinoma. J Gastrointest Oncol Feb. 2024;29(1):346\u201355.","journal-title":"J Gastrointest Oncol Feb"},{"issue":"12","key":"4342_CR22","doi-asserted-by":"publisher","first-page":"7860","DOI":"10.1097\/JS9.0000000000001819","volume":"1","author":"M Cai","year":"2024","unstructured":"Cai M, Liang L, Zhang J, Chen N, Huang W, Guo Y, et al. Lenvatinib plus drug-eluting bead transarterial chemoembolization with\/without hepatic arterial infusion chemotherapy for hepatocellular carcinoma larger than 7\u00a0cm with major portal vein tumor thrombosis: a multicenter retrospective cohort study. Int J Surg Dec. 2024;1(12):7860\u201370.","journal-title":"Int J Surg Dec"},{"issue":"13","key":"4342_CR23","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1158\/1078-0432.CCR-23-3978","volume":"1","author":"JW Han","year":"2024","unstructured":"Han JW, Lee SK, Kwon JH, Nam SW, Yang H, Bae SH, et al. A machine learning algorithm facilitates prognosis prediction and treatment selection for barcelona clinic liver cancer stage c hepatocellular carcinoma. Clin Cancer Res Jul. 2024;1(13):2812\u201321.","journal-title":"Clin Cancer Res Jul"},{"issue":"1","key":"4342_CR24","doi-asserted-by":"publisher","first-page":"e010035","DOI":"10.1136\/jitc-2024-010035","volume":"16","author":"L Li","year":"2025","unstructured":"Li L, Xu X, Wang W, Huang P, Yu L, Ren Z, et al. Safety and efficacy of PD-1 inhibitor (sintilimab) combined with transarterial chemoembolization as the initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria. J Immunother Cancer Jan. 2025;16(1):e010035.","journal-title":"J Immunother Cancer Jan"},{"key":"4342_CR25","doi-asserted-by":"crossref","unstructured":"Yan J, Deng M, Kong S, Li T, Lei Z, Zhang L et al. Transarterial chemoembolization in combination with programmed death-1\/programmed cell death-ligand 1 immunotherapy for hepatocellular carcinoma: A mini review. iLIVER. 2022;1(4):225\u2009\u2013\u200934.","DOI":"10.1016\/j.iliver.2022.10.001"},{"issue":"8","key":"4342_CR26","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1111\/liv.15953","volume":"44","author":"Y Qin","year":"2024","unstructured":"Qin Y, Han S, Yu Y, Qi D, Ran M, Yang M, et al. Lenvatinib in hepatocellular carcinoma: Resistance mechanisms and strategies for improved efficacy. Liver Int Aug. 2024;44(8):1808\u201331.","journal-title":"Liver Int Aug"},{"key":"4342_CR27","doi-asserted-by":"publisher","first-page":"113662","DOI":"10.1016\/j.intimp.2024.113662","volume":"10","author":"S Chen","year":"2025","unstructured":"Chen S, Zhao L, Wu Z, Cai H, Wang F, Wu L, et al. Identification of prognostic tumor microenvironment in patients with advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors. Int Immunopharmacol Jan. 2025;10:144:113662.","journal-title":"Int Immunopharmacol Jan"},{"issue":"3","key":"4342_CR28","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1007\/s00262-025-03942-3","volume":"1","author":"H Cai","year":"2025","unstructured":"Cai H, Chen S, Tang S, Xiao Y, Shi F, Wu Z, et al. Lenvatinib and tislelizumab versus atezolizumab and bevacizumab in combination with TAE-HAIC for unresectable hepatocellular carcinoma with high tumor burden: a multicenter retrospective cohort study. Cancer Immunol Immunother Feb. 2025;1(3):88.","journal-title":"Cancer Immunol Immunother Feb"},{"issue":"15suppl","key":"4342_CR29","doi-asserted-by":"publisher","first-page":"e16173","DOI":"10.1200\/JCO.2021.39.15_suppl.e16173","volume":"39","author":"W Zhang","year":"2021","unstructured":"Zhang W, Lu S, Hu B, Wan T, Wang H, Han J, et al. PD-1 inhibitor combined with lenvatinib for unresectable liver cancer as the conversion therapy: An open-label, non-randomized, phase IV study. J Clin Oncol. 2021;39(15suppl):e16173\u201316173.","journal-title":"J Clin Oncol"},{"issue":"16\u2013Sup","key":"4342_CR30","first-page":"1","volume":"41","author":"W Dong","year":"2023","unstructured":"Dong W, Zhang S, Huo Z, Lu J, Liu H, Wang P, et al. Lenvatinib in combination with PD-1 inhibitor and hepatic arterial infusion chemotherapy (HAIC) for patients with potentially resectable hepatocellular carcinoma: A retrospective analysis. J Clin Oncol. 2023;41(16\u2013Sup):1.","journal-title":"J Clin Oncol"},{"issue":"6","key":"4342_CR31","first-page":"1680","volume":"9","author":"DM Girardi","year":"2023","unstructured":"Girardi DM, Sousa LP, Miranda TA, Haum FNC, Pereira GCB, Pereira AAL. Systemic therapy for advanced hepatocellular carcinoma: current stand and perspectives. cancers (Basel). Mar. 2023;9(6):1680.","journal-title":"Mar"},{"key":"4342_CR32","doi-asserted-by":"crossref","unstructured":"Kudo M. Systemic therapy for hepatocellular carcinoma: latest advances. cancers (Basel). 2018;10(11): 412.","DOI":"10.3390\/cancers10110412"},{"issue":"3","key":"4342_CR33","doi-asserted-by":"publisher","first-page":"100394","DOI":"10.1016\/j.jgeb.2024.100394","volume":"22","author":"K Sayed Amr","year":"2024","unstructured":"Sayed Amr K, Mohamed Ezzat W, Ibrahim Saleh A, Heiba A, Amin H, Refaat Kamel R, et al. Measuring the differential expression of the major hypermethylated tumor suppressor genes in tissues of primary hepatocellular carcinoma. J Genet Eng Biotechnol Sep. 2024;22(3):100394.","journal-title":"J Genet Eng Biotechnol Sep"},{"issue":"18","key":"4342_CR34","doi-asserted-by":"publisher","first-page":"7385","DOI":"10.1158\/0008-5472.CAN-09-1089","volume":"15","author":"Y Hoshida","year":"2009","unstructured":"Hoshida Y, Nijman SM, Kobayashi M, Chan JA, Brunet JP, Chiang DY, et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res Sep. 2009;15(18):7385\u201392.","journal-title":"Cancer Res Sep"},{"key":"4342_CR35","doi-asserted-by":"publisher","first-page":"1035276","DOI":"10.3389\/fimmu.2022.1035276","volume":"13","author":"J Wei","year":"2022","unstructured":"Wei J, Yang Y, Wang G, Liu M. Current landscape and future directions of bispecific antibodies in cancer immunotherapy. Front Immunol. 2022;13:1035276.","journal-title":"Front Immunol"},{"key":"4342_CR36","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.addr.2020.07.003","volume":"154\u2013155","author":"Y Matsumura","year":"2020","unstructured":"Matsumura Y. Cancer stromal targeting therapy to overcome the pitfall of EPR effect. Adv Drug Deliv Rev. 2020;154\u2013155:142\u201350.","journal-title":"Adv Drug Deliv Rev"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-026-04342-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-026-04342-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-026-04342-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T22:28:02Z","timestamp":1782167282000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12957-026-04342-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4342"],"URL":"https:\/\/doi.org\/10.1186\/s12957-026-04342-2","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,1]]},"assertion":[{"value":"10 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the study are appropriately investigated and resolved. This study was approved by the Ethics Committee of the Affiliated Hospital of Xuzhou Medical University (No. XYFY2023-KL116-01), and all procedures were conducted in accordance with the principles of the Declaration of Helsinki (as revised in 2013). As a retrospective study, the requirement for informed consent was waived by the institutional review board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"263"}}